Clinical Trial Update: CY503 for the Treatment of Malignant Melanoma Stage IV After Failure of Prior Therapy [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating CY503 for metastatic melanoma (Stage IV) after prior therapy has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• CY503

Snippet

Sponsor: Cytavis Biopharma GmbH | Conditions: Melanoma | Phase 2 | Status: COMPLETED